Crossmark

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research

Crossref DOI link: https://doi.org/10.1136/rmdopen-2020-001374

Published Online: 2020-11-13

Published Print: 2020-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Kerschbaumer, Andreas https://orcid.org/0000-0002-6685-8873
Smolen, Josef S

Nash, Peter https://orcid.org/0000-0002-2571-788X
Doerner, Thomas https://orcid.org/0000-0002-6478-7725
Dougados, Maxime

Fleischmann, Roy https://orcid.org/0000-0002-6630-1477
Geissler, Klaus

McInnes, Iain B https://orcid.org/0000-0003-4449-8501
Takeuchi, Tsutomu

Trauner, Michael

Winthrop, Kevin

de Wit, Maarten https://orcid.org/0000-0002-8428-6354
Boehncke, Wolf-Henning

Falzon, Louise

van der Heijde, Desirée https://orcid.org/0000-0002-5781-158X
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct00550043 at ClinicalTrials.gov

Documents that mention this clinical trial

Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
https://doi.org/10.1136/ard-2023-223850

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research
https://doi.org/10.1136/rmdopen-2020-001374
License Information

Version of Record valid from 2020-08-17